Posted On: 02/26/2015 1:17:30 PM
Post# of 1040
I forget the exact requirements, but the share price could easily be fixed higher.
Not sure if there's a valuation requirement, but if there is, I could see that holding them back potentially. They already have sales of around 500K+ each quarter, and many biotechs uplist without having any revenues at all. If it can be done, I'm guessing that management has at least considered the prospects of uplisting.
Not sure if there's a valuation requirement, but if there is, I could see that holding them back potentially. They already have sales of around 500K+ each quarter, and many biotechs uplist without having any revenues at all. If it can be done, I'm guessing that management has at least considered the prospects of uplisting.
(0)
(0)
